Sativex cost saving in patients with MS-related spasticity
نویسندگان
چکیده
منابع مشابه
Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Corticospinal Modulation
Sativex is an emergent treatment option for spasticity in patients affected by multiple sclerosis (MS). This oromucosal spray, acting as a partial agonist at cannabinoid receptors, may modulate the balance between excitatory and inhibitory neurotransmitters, leading to muscle relaxation that is in turn responsible for spasticity improvement. Nevertheless, since the clinical assessment may not b...
متن کاملqfd planning with cost consideration in fuzzy environment
در عصر حاضر که رقابت بین سازمان ها بسیار گسترش یافته است، مطالعه و طرحریزی سیستم های تولیدی و خدماتی به منظور بهینه سازی عملکرد آنها اجتناب ناپذیر می باشد. بخش عمده ای از رقابت پذیری سازمان ها نتیجه رضایتمندی مشتریان آنها است. میزان موفقیت سازمان های امروزی به تلاش آنها در جهت شناسایی خواسته ها و نیازهای مشتریان و ارضای این نیازها بستگی دارد. از طرفی کوتاه کردن زمان ارائه محصول/خدمات به مشتریان...
15 صفحه اولOverview of MS spasticity.
ported spasticity, compared with patients who did not experience spasticity, in terms of spasms, urinary dysfunction and sleep disturbances in a recent study is highlighted in table 1 [4] . The effect of spasticity on mobility is one of the most disabling changes associated with MS and it has a marked negative impact on patient well-being and quality of life [4–6] . It also increases the cost-b...
متن کاملSativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study)
BACKGROUND The approval of Sativex for the management of multiple sclerosis (MS) spasticity opened a new opportunity to many patients. In Italy, the healthcare payer can be fully reimbursed by the involved pharma company with the cost of treatment for patients not responding after a 4 week (28 days) trial period (Payment by Results, PbR), and 50% reimbursed with the cost of 6 weeks (42 days) tr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pharmacoeconomics & Outcomes News
سال: 2021
ISSN: ['1173-5503', '1179-2043']
DOI: https://doi.org/10.1007/s40274-021-7667-2